40 / 74
CARDIOVASCULAR JOURNAL OF AFRICA • Volume 28, No 5, September/October 2017
314
AFRICA
of regional right ventricular function after thrombolysis for pulmonary
embolism.
Am J Cardiol
1999;
83
: 804–806. PMID: 10080447.
22. Zornoff LA, Skali H, Pfeffer MA, St John Sutton M, Rouleau JL,
Lamas GA,
et al
. Right ventricular dysfunction and risk of heart failure
and mortality after myocardial infarction.
J Am Coll Cardiol
2002;
39
:
1450–1455. PMID: 11985906.
23. Giusca S, Dambrauskaite V, Scheurwegs C, D’Hooge J, Claus P,
Herbots L,
et al.
Deformation imaging describes right ventricular func-
tion better than longitudinal displacement of the tricuspid ring.
Heart
2010;
96
: 281–288. PMID: 19720609.
24. Pirat B, McCulloch ML, Zoghbi WA. Evaluation of global and regional
right ventricular systolic function in patients with pulmonary hyperten-
sion using a novel speckle tracking method.
Am J Cardiol
2006;
98
:
699–704. PMID: 16923465.
25. Park JH, Park MM, Farha S, Sharp J, Lundgrin E, Comhair S,
et al
.
Impaired global right ventricular longitudinal strain predicts long-term
adverse outcomes in patients with pulmonary arterial hypertension.
J
Cardiovasc Ultrasound
2015;
23
: 91–99. PMID: 26140151.
26. Carlsson M, Ugander M, Heiberg E, Arheden H. The quantitative
relationship between longitudinal and radial function in left, right, and
total heart pumping in humans.
Am J Physiol Heart Circ Physiol
2007;
293
: H636–644. PMID: 17307988.
27. Park JH, Kusunose K, Motoki H, Kwon DH, Grimm RA, Griffin BP,
et al
. Assessment of right ventricular longitudinal strain in patients
with ischemic cardiomyopathy: head-to-head comparison between
two-dimensional speckle-based strain and velocity vector imaging using
volumetric assessment by cardiac magnetic resonance as a “gold stand-
ard”.
Echocardiography
2015;
32
: 956–965. PMID: 25231541.
28. Park SJ, Park JH, Lee HS, Kim MS, Park YK, Park Y,
et al.
Impaired RV global longitudinal strain is associated with poor long-
term clinical outcomes in patients with acute inferior STEMI.
J Am Coll
CardiolCardiovasc Imag
2015;
8
: 161–169. PMID: 25577444.
Confidence Through Clinical and Real World Experience
1-3
Millions of Patients Treated Worldwide Across Multiple Indications
4
#1 Scripted Non-VKA Oral Anticoagulant by Cardiologists*
*Impact RX Data 2016
NOAC: Non Vitamin K Oral Anticoagulant
REFERENCES:
1. Patel M.R., Mahaffey K.W., Garg J.
et al
. Rivaroxaban versus warfarin in non-valvular atrial fi brillation.
N Engl J Med
. 2011;365(10):883–91. 2. Tamayo S., Peacock W.F., Patel M.R.,
et al
. Characterizing
major bleeding in patients with nonvalvular atrial fi brillation: A pharmacovigilance study of 27 467 patients taking rivaroxaban.
Clin Cardiol
. 2015;38(2):63–8. 3. Camm A.J., Amarenco P., Haas S.
et al
. XANTUS: A
Real-World, Prospective, Observational Study. 4. Calculation based on IMS Health MIDAS, Database: Monthly Sales January 2017.
S4 Xarelto 15: Each film-coated tablet contains rivaroxaban 15 mg. Reg. No: 46/8.2/0111; Namibia NS2 : 12/8.2/0006; S2 Botswana: BOT1302296; Zimbabwe: PP10 Reg. 2017/10.2/5363
S4 Xarelto 20: Each film-coated tablet contains rivaroxaban 20 mg. Reg. No: 46/8.2/0112;Namibia NS2 : 12/8.2/0007; S2 Botswana: BOT1302297; Zimbabwe: PP10 Reg. 2017/10.2/5364
PHARMACOLOGICAL CLASSIFICATION:
A.8.2 Anticoagulants.
INDICATIONS:
(1) Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (SPAF); (2) Treatment of deep vein thrombosis
(DVT) and for the prevention of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE); (3) Treatment of pulmonary embolism (PE) and for the prevention of recurrent pulmonary embolism (PE) and deep
vein thrombosis (DVT). For full prescribing information, refer to the package insert approved by the Medicines Regulatory Authority (MCC).
HCR:
Bayer (Pty) Ltd, Co. Reg. No.: 1968/011192/07, 27 Wrench Road, Isando,
1609. Tel: 011 921 5044 Fax: 011 921 5041.
L.ZA.MKT.GM06.2017.1808
© Bayer June 2017